Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels

  Assays can detect more than 90 different disease pathogens

CARLSBAD, Calif.--()--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.

To effectively study outbreaks and determine disease etiology where pathogens are similar, analytically sensitive panels are needed to support laboratory research. TrueMark Infectious Disease Research Panels are analytically sensitive, real-time polymerase chain reaction (PCR) syndromic panels for the analysis of a wide range of infectious disease pathogens.

Leveraging real-time PCR technology, the predefined and customizable panel options allow researchers to choose from more than 90 different bacterial and viral strain assays to generate results within four hours from taking the samples.

“With the TrueMark Infectious Disease Research Panels, laboratories can choose either the readymade panels or create their own custom panels to suit their needs,” said Dr. Manoj Gandhi, senior medical director of Genetic Testing Solutions at Thermo Fisher Scientific. “By providing the flexibility to choose panels for researching polymicrobial infections, laboratories can now expand their testing menus using existing instrumentation and offer the benefits of PCR testing for researching a broad range of markers that can cause infectious disease.”

The assays use pre-spotted and dried down TaqMan plates, which are designed to enable easy set-up and increased accuracy. Testing can be done from nasopharyngeal swabs or nasopharyngeal aspirate, vaginal, genital and lesion swabs or urine samples. These samples can also be prepared using workflows that currently exist in most labs that use the Applied Biosystems MagMAX Viral/Pathogen kits automated on a KingFisher Purification System instrument and mixed with the Applied Biosystems multiplex master mix onto a 96-well or 384-well plate.

The panels are optimized for use on QuantStudio qPCR systems with verified sample-to-answer workflow and provide easy to read results with the Applied Biosystems QuantStudio Design and Analysis Software v2.6. For more information on the TrueMark Infectious Disease Research Panels, please visit www.thermofisher.com/truemarkpluspanels.

For Research Use Only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:

Mauricio Minotta
Phone: 760-805-5266
E-mail: Mauricio.Minotta@thermofisher.com

Ariane Lovell
Phone: 646-307-6317
Email: Ariane.lovell@finnpartners.com

Contacts

Media:

Mauricio Minotta
Phone: 760-805-5266
E-mail: Mauricio.Minotta@thermofisher.com

Ariane Lovell
Phone: 646-307-6317
Email: Ariane.lovell@finnpartners.com